NME6

NME6 is a mitochondria-localized member of the NME/NDP kinase family that governs pyrimidine ribonucleotide supply and mitochondrial gene expression at the inner membrane/matrix interface (PMID:34789336, PMID:37548337). Unlike canonical NMEs, recombinant NME6 is monomeric, does not oligomerize with NME1–NME4, and lacks intrinsic phospho-histidine-dependent NDP kinase activity on its own (PMID:34789336). Catalytic competence is instead conferred through direct physical interaction with the mitochondrial ribosome assembly/translation factor RCC1L, with which it forms a heterodimeric complex; in this complex NME6 functions as a nucleoside diphosphate kinase that converts pyrimidine rNDPs to rNTPs (PMID:34789336, PMID:39120309, PMID:37548337). Loss of NME6 depletes mitochondrial transcripts and destabilizes the electron transport chain, and its overexpression reduces ADP-stimulated respiration and complex III abundance, tying NME6 to oxidative phosphorylation through control of the mitochondrial rNTP pool (PMID:34789336, PMID:37548337). Beyond this mitochondrial role, overexpression and knockdown studies implicate NME6 in cytokinesis and cell-cycle progression (PMID:10618642), embryonic stem cell self-renewal and pluripotency marker expression (PMID:22899353), and breast cancer cell migration, EMT marker regulation, and MAPK/ERK signaling (PMID:39273527).

1. 1999 Medium

   Initial characterization asked whether the NME-family member NME6 was itself a catalytically active NDP kinase and where it acted in the cell, establishing it as a mitochondrial protein with apparent phosphotransferase activity.

   Evidence In vitro enzymatic assay with recombinant protein plus immunofluorescence colocalization and subcellular fractionation

   PMID:10618642

   Open questions at the time

   • In vitro activity later contradicted by more rigorous biochemistry
   • Mitochondrial submembrane location not resolved
   • No physiological substrate defined
2. 1999 Medium

   Inducible overexpression tested NME6's cellular consequences, linking elevated NME6 to growth suppression and a cytokinesis/cell-cycle defect.

   Evidence Cre-loxP inducible overexpression in SAOS2 cells with flow cytometry and morphology analysis

   PMID:10618642

   Open questions at the time

   • Overexpression phenotype may not reflect endogenous function
   • Mechanism connecting NME6 to cytokinesis unknown
   • Single cell line
3. 2012 Medium

   Loss- and gain-of-function in mouse ESCs asked whether NME6 contributes to stemness, establishing it as required for pluripotency marker expression and self-renewal.

   Evidence shRNA knockdown with overexpression rescue, pluripotency marker readouts, embryoid body and teratoma assays in mESCs

   PMID:22899353

   Open questions at the time

   • Molecular mechanism linking NME6 to pluripotency network not defined
   • Relationship to its mitochondrial role unclear
   • Single lab
4. 2021 High

   Rigorous recombinant biochemistry revisited the catalytic question, showing NME6 is monomeric, forms no phospho-histidine intermediate, and lacks intrinsic NDPK activity, overturning the 1999 activity claim.

   Evidence Recombinant protein oligomerization assays, phospho-histidine detection, and NDPK activity assays

   PMID:34789336

   Open questions at the time

   • Did not yet explain how NME6 could be active in vivo
   • No partner-dependent activation tested here
5. 2021 Medium

   The same study refined NME6 localization and identified its physical partners, placing it at the inner membrane/matrix and showing direct interaction with RCC1L plus association with NME4 and OPA1, and linking NME6 to OXPHOS.

   Evidence Subcellular fractionation, confocal microscopy, co-IP/pulldown interaction screen, respiration assay, and complex III quantification

   PMID:34789336

   Open questions at the time

   • Direct interaction with NME4/OPA1 not demonstrated
   • Functional consequence of RCC1L binding not yet established
   • OXPHOS effect from overexpression only
6. 2023 Medium

   Genetic loss-of-function with metabolite profiling defined NME6's physiological output, showing it acts as a mitochondrial NDP kinase converting pyrimidine rNDPs to rNTPs whose loss depletes mitochondrial transcripts and destabilizes the ETC.

   Evidence NME6 deletion/depletion, rNTP metabolite profiling, mitochondrial transcript quantification, and ETC complex analysis

   PMID:37548337

   Open questions at the time

   • Reported via commentary on the primary study
   • Quantitative contribution to total matrix rNTP pool not stated
   • Substrate selectivity for pyrimidines mechanistically unexplained
7. 2024 Medium

   Reconstitution resolved the apparent activity paradox by showing NME6 gains NDP kinase activity upon heterodimerizing with RCC1L, challenging the canonical hexamerization requirement for NME catalysis.

   Evidence Biochemical reconstitution of the NME6–RCC1L complex with NDPK activity assay (review context citing primary work)

   PMID:39120309

   Open questions at the time

   • Full primary data details not in this corpus
   • Heterodimer stoichiometry/structure not resolved
   • Mechanism of activation by RCC1L unknown
8. 2024 Medium

   Cancer cell studies extended NME6's roles beyond mitochondrial metabolism, linking it to migration, EMT marker regulation, DNA-damage-dependent cell-cycle changes, and MAPK/ERK signaling.

   Evidence Overexpression and siRNA silencing in MDA-MB-231T cells with wound-healing, flow cytometry, and Western blot for EMT/MAPK markers

   PMID:39273527

   Open questions at the time

   • Connection between mitochondrial NDPK function and ERK signaling not defined
   • Effects largely from overexpression
   • Single cell line

• How NME6's mitochondrial rNTP-supply function mechanistically connects to its reported roles in pluripotency, cytokinesis, and MAPK/ERK signaling remains unresolved.
• No structural model of the NME6–RCC1L heterodimer
• Causal link between matrix rNTP pools and cytoplasmic signaling phenotypes unestablished
• Physiological vs overexpression-driven roles not reconciled